Efficacy and safety of Tenofovir Disoproxil Fumarate in Egyptian patients with chronic hepatitis B virus infection
Othman, O., Kamal, S. (2024). Efficacy and safety of Tenofovir Disoproxil Fumarate in Egyptian patients with chronic hepatitis B virus infection. EKB Journal Management System, 6(1), 20-32. doi: 10.21608/jmals.2024.260653.1016
Othman Ali Othman; Sahar Sayed Kamal. "Efficacy and safety of Tenofovir Disoproxil Fumarate in Egyptian patients with chronic hepatitis B virus infection". EKB Journal Management System, 6, 1, 2024, 20-32. doi: 10.21608/jmals.2024.260653.1016
Othman, O., Kamal, S. (2024). 'Efficacy and safety of Tenofovir Disoproxil Fumarate in Egyptian patients with chronic hepatitis B virus infection', EKB Journal Management System, 6(1), pp. 20-32. doi: 10.21608/jmals.2024.260653.1016
Othman, O., Kamal, S. Efficacy and safety of Tenofovir Disoproxil Fumarate in Egyptian patients with chronic hepatitis B virus infection. EKB Journal Management System, 2024; 6(1): 20-32. doi: 10.21608/jmals.2024.260653.1016

Efficacy and safety of Tenofovir Disoproxil Fumarate in Egyptian patients with chronic hepatitis B virus infection

Journal of Medical and Life Science
Volume 6, Issue 1, March 2024, Page 20-32  XML PDF (1.2 MB)
Document Type: Original Article
DOI: 10.21608/jmals.2024.260653.1016
View on SCiNiTO View on SCiNiTO
Authors
Othman Ali Othman email orcid 1; Sahar Sayed Kamal2
1Chemistry department (Biochemistry Division)-Faculty of Science-Minia University-ElMinia-Egypt
2Malawi Specialized Hospital (Laboratory Department) Malawi, Minia, Egypt
Abstract
Background: Hepatitis B virus (HBV) infection is a major global health problem leading to severe liver diseases such as cirrhosis and hepatocellular carcinoma. Tenofovir Disoproxil Fumarate (TDF) is an orally bioavailable prodrug of Tenofovir. This study aimed to evaluate the efficacy and safety of long-term TDF therapy in Egyptian Chronic Hepatitis B patients, Objective: Assessment of effectiveness and safety of TDF therapy in Egyptian HBV patients. Materials and Methods: HBV was confirmed by detection of both HBsAg and HBV DNA. All patients were given antiviral drug (300 mg TDF, oral, once a day for 3 months). Results: Before treatment; HBV Patients showed significant elevation in Ferritin, Albumin, S. Creatinine, AST, ALT, PO4, INR, and PT compared to the healthy volunteers’ group. Additionally showed a decrease in AFP, DB, TB, PC, PLT, and WBCs again in comparison to the control group. After receiving HBV TDF, the same group of patients showed a significant increase in Ferritin, S. Creatinine, TB, PC, WBCs, and Hb% and a significant decrease in PO4, Albumin, INR, and PT compared to pre-treatment conditions. Conclusion: we show clear benefits of TDF therapy in ethnically diverse CHB populations, even among patients with only mild/moderate liver disease at baseline.
Keywords
Hepatitis B virus; Tenofovir Disoproxil Fumarate; Alfa fetoprotein; Ferritin; liver enzymes
Statistics
Article View: 62
PDF Download: 40